METTL1 and hepatocellular carcinoma: Analysis of the TCGA‐LIHC data revealed that 15.4% of HCC patients present the amplification of METTL1 DNA (Figure S1G) and the METTL1 mRNA expression is significantly elevated in patients with METTL1 DNA amplification (Figure S1H).